Abstract
BACKGROUND. Limited information is available regarding the cardiac and pulmonary effects of high dose chemotherapy (HDCT) and autologous peripheral blood progenitor cell (PBPC) transplantation. METHODS. The authors evaluated cardiac and pulmonary function after BEAM (BCNU 300 mg/m2, etoposide 400 mg/m2/day x 3 days, cytosine arabinoside 200 mg/m2/day x 4 days, and melphalan 140 mg/m2), HDCT, and PBPC transplantation in 26 patients with non-Hodgkin's lymphoma or Hodgkin's disease. Therapy prior to BEAM included doxorubicin (25 patients), bleomycin (6 patients), and mediastinal irradiation (4 patients). All patients had pulmonary function tests (PFTs) and equilibrium radionuclide angiography before and at a median of 57 weeks after transplantation. RESULTS. Prior to high dose therapy, 8 patients had abnormal PFTs, including 6 with a diffusing capacity of the lung for carbon monoxide (DLCO) <70% of predicted value. At the time of reevaluation after HDCT, all patients included in the study were in complete remission, and none had received additional therapy after transplantation. At a median of 77 weeks after transplantation, none of the patients had cardiac or pulmonary symptoms. Moreover, there were no significant changes in total lung capacity, forced vital capacity, forced expiratory volume in 1 second/forced vital capacity, DLCO, or left ventricular ejection fraction values when compared with baseline studies. CONCLUSIONS. The authors concluded that HDCT with BEAM and PBPC transplantation did not result in significant cardiac or pulmonary toxicity, even in patients with borderline pretransplantation PFT values. Further studies of patients undergoing HDCT and PBPC transplantation are needed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1506-1512 |
| Number of pages | 7 |
| Journal | Cancer |
| Volume | 82 |
| Issue number | 8 |
| DOIs | |
| State | Published - Apr 15 1998 |
Fingerprint
Keywords
- BEAM
- Cardiac toxicity
- High dose chemotherapy
- Peripheral blood progenitor cell transplantation
- Pulmonary toxicity
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. / Salloum, Emile; Jillella, Anand P.; Nadkarni, Rajani; Seropian, Stuart; Hu, Grace L.; D'Andrea, Elizabeth; Zelterman, Daniel; Cooper, Dennis L.
In: Cancer, Vol. 82, No. 8, 15.04.1998, p. 1506-1512.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation
AU - Salloum, Emile
AU - Jillella, Anand P.
AU - Nadkarni, Rajani
AU - Seropian, Stuart
AU - Hu, Grace L.
AU - D'Andrea, Elizabeth
AU - Zelterman, Daniel
AU - Cooper, Dennis L.
PY - 1998/4/15
Y1 - 1998/4/15
N2 - BACKGROUND. Limited information is available regarding the cardiac and pulmonary effects of high dose chemotherapy (HDCT) and autologous peripheral blood progenitor cell (PBPC) transplantation. METHODS. The authors evaluated cardiac and pulmonary function after BEAM (BCNU 300 mg/m2, etoposide 400 mg/m2/day x 3 days, cytosine arabinoside 200 mg/m2/day x 4 days, and melphalan 140 mg/m2), HDCT, and PBPC transplantation in 26 patients with non-Hodgkin's lymphoma or Hodgkin's disease. Therapy prior to BEAM included doxorubicin (25 patients), bleomycin (6 patients), and mediastinal irradiation (4 patients). All patients had pulmonary function tests (PFTs) and equilibrium radionuclide angiography before and at a median of 57 weeks after transplantation. RESULTS. Prior to high dose therapy, 8 patients had abnormal PFTs, including 6 with a diffusing capacity of the lung for carbon monoxide (DLCO) <70% of predicted value. At the time of reevaluation after HDCT, all patients included in the study were in complete remission, and none had received additional therapy after transplantation. At a median of 77 weeks after transplantation, none of the patients had cardiac or pulmonary symptoms. Moreover, there were no significant changes in total lung capacity, forced vital capacity, forced expiratory volume in 1 second/forced vital capacity, DLCO, or left ventricular ejection fraction values when compared with baseline studies. CONCLUSIONS. The authors concluded that HDCT with BEAM and PBPC transplantation did not result in significant cardiac or pulmonary toxicity, even in patients with borderline pretransplantation PFT values. Further studies of patients undergoing HDCT and PBPC transplantation are needed.
AB - BACKGROUND. Limited information is available regarding the cardiac and pulmonary effects of high dose chemotherapy (HDCT) and autologous peripheral blood progenitor cell (PBPC) transplantation. METHODS. The authors evaluated cardiac and pulmonary function after BEAM (BCNU 300 mg/m2, etoposide 400 mg/m2/day x 3 days, cytosine arabinoside 200 mg/m2/day x 4 days, and melphalan 140 mg/m2), HDCT, and PBPC transplantation in 26 patients with non-Hodgkin's lymphoma or Hodgkin's disease. Therapy prior to BEAM included doxorubicin (25 patients), bleomycin (6 patients), and mediastinal irradiation (4 patients). All patients had pulmonary function tests (PFTs) and equilibrium radionuclide angiography before and at a median of 57 weeks after transplantation. RESULTS. Prior to high dose therapy, 8 patients had abnormal PFTs, including 6 with a diffusing capacity of the lung for carbon monoxide (DLCO) <70% of predicted value. At the time of reevaluation after HDCT, all patients included in the study were in complete remission, and none had received additional therapy after transplantation. At a median of 77 weeks after transplantation, none of the patients had cardiac or pulmonary symptoms. Moreover, there were no significant changes in total lung capacity, forced vital capacity, forced expiratory volume in 1 second/forced vital capacity, DLCO, or left ventricular ejection fraction values when compared with baseline studies. CONCLUSIONS. The authors concluded that HDCT with BEAM and PBPC transplantation did not result in significant cardiac or pulmonary toxicity, even in patients with borderline pretransplantation PFT values. Further studies of patients undergoing HDCT and PBPC transplantation are needed.
KW - BEAM
KW - Cardiac toxicity
KW - High dose chemotherapy
KW - Peripheral blood progenitor cell transplantation
KW - Pulmonary toxicity
UR - http://www.scopus.com/inward/record.url?scp=0032523083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032523083&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0142(19980415)82:8<1506::AID-CNCR12>3.0.CO;2-8
DO - 10.1002/(SICI)1097-0142(19980415)82:8<1506::AID-CNCR12>3.0.CO;2-8
M3 - Article
C2 - 9554528
AN - SCOPUS:0032523083
VL - 82
SP - 1506
EP - 1512
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 8
ER -